The acquisition, the price of which was not disclosed, expands Precision for Medicineʼs presence in Europe, giving it a base in Budapest, in addition to others in Edinburgh, Paris, Berlin, Geneva, Bucharest, Bratislava and Belgrade.
“The addition of the Argint team augments and enhances our European platform, which is critical due to the significant number of customers we have throughout Europe – and also the number of sites and patients seeking novel therapies derived from the benefits of precision medicine,” said Precision for Medicine President Chad Clark.
Argint International CEO Agnes Pinnel said the transaction “offers growth potential for our people.”
“In particular, we are excited to join with a leader in biomarker-based precision medicine programs, one of the fastest growing and important parts of drug development,” she added.
Precision for Medicine supports life sciences companies in the use of biomarkers necessary for targeting patients more precisely and effectively, according to the MTI report.
Argint International had after-tax profit of HUF 1.2 billion on revenue of HUF 4.2 bln last year, public records show.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
